Brazil’s health regulator rejected the use of the Sinovac dose in minors

After several months of waiting, the National Health Surveillance Agency of Brazil (Anvisa) I decided unanimously reject the request of the Chinese laboratory Sinovac to apply the doses of its candidate, Coronavac, in minors. He did leave the door open for future approval requests, though.

According to the highest sanitary regulator of the South American giant, the Chinese pharmacist requested almost four months ago the respective approval of Anvisa of its inoculant serum in pediatric version, an antiviral compound that is already applied in China in children between the ages of three and 17, given the high levels of safety and efficacy shown by the drug in clinical trials.

Leave a Comment